S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The single greatest medical breakthrough of all time? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The single greatest medical breakthrough of all time? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The single greatest medical breakthrough of all time? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The single greatest medical breakthrough of all time? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The single greatest medical breakthrough of all time? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The single greatest medical breakthrough of all time? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The single greatest medical breakthrough of all time? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The single greatest medical breakthrough of all time? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
NASDAQ:IOVA

Iovance Biotherapeutics - IOVA Stock Forecast, Price & News

$6.84
+0.43 (+6.71%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.28
$6.89
50-Day Range
$5.95
$10.24
52-Week Range
$5.42
$20.60
Volume
14.07 million shs
Average Volume
4.03 million shs
Market Capitalization
$1.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.40

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
227.5% Upside
$22.40 Price Target
Short Interest
Healthy
12.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.86mentions of Iovance Biotherapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$65.13 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.50) to ($2.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

74th out of 1,034 stocks

Biological Products, Except Diagnostic Industry

11th out of 171 stocks

IOVA stock logo

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Stock News Headlines

Iovance Biotherapeutics Recent Insider Activity
Iovance Declines Following FDA Feedback On Its Melanoma Drug Lifileucel
Robert W. Baird Keeps Their Buy Rating on SAB Biotherapeutics (SABS)
Recap: Iovance Biotherapeutics Q3 Earnings
IOVA Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics to Present Posters at ESMO 2022
Expert Ratings for Iovance Biotherapeutics
Iovance: TIL Cell Therapy Set To Prove Itself
7 Analysts Have This to Say About Iovance Biotherapeutics
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Company Calendar

Last Earnings
11/04/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
319
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.40
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+227.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-342,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.49 per share

Miscellaneous

Free Float
145,845,000
Market Cap
$1.08 billion
Optionable
Optionable
Beta
0.38

Key Executives

  • Dr. Frederick G. Vogt Esq. (Age 48)
    J.D., Ph.D., Interim CEO, Pres, Gen. Counsel & Corp. Sec.
    Comp: $752.81k
  • Mr. Jean-Marc Bellemin M.B.A. (Age 50)
    Chief Financial Officer & Principal Accounting Officer
    Comp: $623.6k
  • Dr. Igor P. Bilinsky (Age 49)
    Chief Operating Officer
    Comp: $577.35k
  • Dr. Friedrich Graf Finckenstein M.D. (Age 55)
    Chief Medical Officer
    Comp: $649.13k
  • Ms. Sara Pellegrino
    VP of Investor Relations & PR
  • Ms. Tracy Winton
    Sr. VP of HR
  • Mr. Howard B. Johnson M.B.A. (Age 62)
    Chief Bus. Officer
  • Mr. James Ziegler M.B.A.
    Exec. VP of Commercial
  • Mr. Madan Jagasia
    Exec. VP of Medical Affairs
  • Dr. Raj K. Puri M.D.
    Ph.D., Exec. VP of Regulatory Strategy & Translational Medicine













IOVA Stock - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price forecast for 2023?

11 Wall Street research analysts have issued 1 year price objectives for Iovance Biotherapeutics' stock. Their IOVA share price forecasts range from $11.00 to $38.00. On average, they expect the company's stock price to reach $22.40 in the next twelve months. This suggests a possible upside of 227.5% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2022?

Iovance Biotherapeutics' stock was trading at $19.09 on January 1st, 2022. Since then, IOVA stock has decreased by 64.2% and is now trading at $6.84.
View the best growth stocks for 2022 here
.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our IOVA earnings forecast
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) released its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.02. During the same period in the prior year, the company earned ($0.40) earnings per share.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.03%), BlackRock Inc. (7.26%), Perceptive Advisors LLC (6.49%), State Street Corp (6.29%), Price T Rowe Associates Inc. MD (2.98%) and Pictet Asset Management SA (2.52%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $6.84.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.08 billion. The biotechnology company earns $-342,250,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

The company employs 319 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 12/4/2022 by MarketBeat.com Staff